Iradimed (NASDAQ:IRMD) Issues Earnings Results, Misses Expectations By $0.05 EPS

Iradimed (NASDAQ:IRMD - Get Free Report) issued its quarterly earnings data on Thursday. The medical equipment provider reported $0.40 earnings per share for the quarter, missing analysts' consensus estimates of $0.45 by ($0.05), Zacks reports. Iradimed had a net margin of 26.12% and a return on equity of 23.99%. The company had revenue of $19.39 million for the quarter, compared to the consensus estimate of $19.09 million. Iradimed updated its Q1 2025 guidance to 0.390-0.430 EPS and its FY 2025 guidance to 1.710-1.810 EPS.

Iradimed Trading Down 0.3 %

Shares of IRMD stock traded down $0.17 on Monday, reaching $55.23. The company's stock had a trading volume of 51,661 shares, compared to its average volume of 36,478. Iradimed has a 1 year low of $40.18 and a 1 year high of $63.29. The company has a market capitalization of $699.76 million, a price-to-earnings ratio of 37.83 and a beta of 0.82. The stock's fifty day simple moving average is $57.20 and its 200-day simple moving average is $52.18.

Iradimed Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, March 5th. Shareholders of record on Monday, February 24th will be issued a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a yield of 1.23%. The ex-dividend date is Monday, February 24th. This is a boost from Iradimed's previous quarterly dividend of $0.15. Iradimed's dividend payout ratio (DPR) is currently 41.10%.

Wall Street Analyst Weigh In

Several research analysts have issued reports on IRMD shares. Roth Mkm reissued a "buy" rating and issued a $72.00 target price (up from $60.00) on shares of Iradimed in a research report on Friday. StockNews.com cut shares of Iradimed from a "strong-buy" rating to a "buy" rating in a research note on Thursday.

Insider Transactions at Iradimed

In other Iradimed news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total transaction of $135,450.00. Following the completion of the transaction, the chief financial officer now directly owns 4,383 shares of the company's stock, valued at $237,470.94. The trade was a 36.32 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 37.10% of the company's stock.

Iradimed Company Profile

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.